Invesco WilderHill Clean Energy ETF vs Smith & Nephew plc — how do they compare? Invesco WilderHill Clean Energy ETF trades at $31.54, while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: Smith & Nephew plc pays a 2.85% dividend while Invesco WilderHill Clean Energy ETF pays none, and Invesco WilderHill Clean Energy ETF is trading nearer its 52-week high, Smith & Nephew plc nearer its low. Which is the better fit depends on your goals.
| PBW | SNN | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $46.99 | $38.53 |
52-Week Low | $24.75 | $27.80 |
Market Cap | — | $11.63B |
Enterprise Value | — | $14.66B |
Dividend Yield | — | 2.85% |
Signals from Pluang's Aura AI — not financial advice
PBW (Invesco WilderHill Clean Energy ETF) trades at $32.38, up 1.86% today, but technical indicators show a bearish trend with moving averages signaling selling pressure. The ETF's unique selection criteria focusing on ecological factors over financial metrics creates an undiversified portfolio that has underperformed broader markets. Recent market volatility from geopolitical tensions and tech sector sell-offs has impacted clean energy ETFs despite long-term growth catalysts.
The clean energy sector faces near-term headwinds from market volatility, though long-term prospects remain supported by global energy security concerns and substantial international investment. PBW's performance remains tied to clean energy adoption trends and policy developments, with current technical weakness suggesting cautious near-term positioning.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Trailing returns across standard periods
PBW is an equal-weighted ETF that invests in U.S. companies leading the clean energy transition. It focuses on renewable energy, power conservation, and sustainable technologies like solar, wind, and energy storage.
Read more on PBW →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →